申请人:Shenyang Pharmaceutical University
公开号:US08349835B2
公开(公告)日:2013-01-08
The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and/or prevention of cancer.
该发明属于制药领域。该发明涉及公式I的化合物,包括其光学活性形式、药学上可接受的盐或水合物,以及包含其作为活性成分的制药组合物;用于制备血管内皮生长因子受体酪氨酸激酶抑制剂,并用于制备用于治疗和/或预防癌症的药物。